Monoclonal antibodies, or mAbs, are important tools in medicine. These laboratory-made proteins are widely used in treatments ...

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.

Ecologists at the School of Biological Sciences of The University of Hong Kong (HKU) have made valuable discoveries that could transform the conservation of two iconic cockatoo species: the Sulfur ...

a first-in-class molecular glue of specific Protein Phosphatase 2A (PP2A) complexes. Rappta’s PP2A-reactivating technologies developed using its proprietary high resolution structural data have the ...

Rappta Therapeutics Oy has signed an exclusive global license agreement with Springworks Therapeutics Inc. for RPT-04402, a first-in-class molecular glue of specific protein phosphatase 2A (PP2A) ...

"We are excited to welcome Dr. Wagner to Neomorph as we rapidly advance our pipeline of novel molecular glue degraders into the clinic," said Phil Chamberlain, DPhil., Co-Founder, President ...

“We are excited to welcome Dr. Wagner to Neomorph as we rapidly advance our pipeline of novel molecular glue degraders into the clinic,” said Phil Chamberlain, DPhil., Co-Founder, President, and Chief ...

BOSTON - Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a biotechnology company with a market capitalization of $568 million and an impressive 203% return over the past year, has ...

BALTIMORE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals, a pioneer in non-degrading molecular glue therapeutics, announced today that it will host an executive roundtable at the WuXi ...